Welcome to our dedicated page for NEWCELX SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NLSPW SEC filings page provides access to regulatory documents that reference the warrants of NLS Pharmaceutics Ltd. and the broader capital structure of the company. As a foreign private issuer, NLS Pharmaceutics files an annual report on Form 20-F and frequent current reports on Form 6-K with the U.S. Securities and Exchange Commission, and these filings often describe transactions that involve warrants, preferred securities, and equity facilities.
For NLSPW, the most relevant filings include Form 6-K reports detailing private placement financings, warrant issuances, warrant exchanges, and pre-funded warrant arrangements. For example, the company has reported securities purchase agreements for preferred shares and preferred participation certificates, associated common share purchase warrants, and a warrant exchange agreement in which an existing warrant was exchanged for common shares under Section 3(a)(9) of the Securities Act. These documents explain how warrants fit into NLS Pharmaceutics’ financing strategy and how they may be adjusted in connection with corporate events.
Filings related to the merger with Kadimastem Ltd. are also important for understanding NLSPW. Through a registration statement on Form F-4 and multiple Form 6-K amendments, NLS Pharmaceutics has disclosed the terms of the Agreement and Plan of Merger, extensions of the termination date, changes to the exchange ratio calculation, and shareholder approvals. Company communications state that, following the merger and reverse share split, the combined company will be named NewCelX Ltd. and listed on Nasdaq under the symbol NCEL, and that currently traded warrants will not be listed for trading post-merger.
On Stock Titan, AI-powered tools can help summarize these filings so readers can quickly see how warrant terms, equity financings, and merger mechanics are described in official documents. Users can review Form 6-K reports for financing and merger updates, the Form F-4 for detailed transaction terms, and the Form 20-F for broader risk factor and capital structure discussions that provide context for NLSPW.
NLS Pharmaceutics Ltd. – Schedule 13D filing (NLSPW)
Chairman Ronald Hafner has filed a Schedule 13D disclosing beneficial ownership of 557,131 common shares, equal to 13.2 % of the company’s 4,097,641 outstanding shares. Mr. Hafner possesses sole voting and dispositive power over the entire position; no shares are held jointly.
Capital deployment was entirely from personal funds. The filing details multiple transactions that built the position:
- Equity Purchase Agreement (10-Oct-2024): acquired 100,807 common shares plus 100,807 five-year warrants (exercise $4.25) at a combined price of $3.97.
- Warrant Amendment (9-Oct-2024): received pre-funded warrants for 1,925 shares, exercisable at CHF 0.80.
- Debt Purchase Agreement (10-Oct-2024): obtained 173,173 convertible preferred shares (conversion price $4.96) as part of a $4 m debt restructuring.
- Put-Call Agreement (Feb-2025): option exercised leading to purchase of 37,783 preferred shares for $150,000.
- Debt settlements: 111,637 common shares transferred from CEO Alexander Zwyer (7-Feb-2025) and 17,782 shares transferred from Magnetic Rock Investment AG (21-Feb-2025).
Intent: The shares are held for investment; no activist agenda is disclosed. The agreements grant limited participation rights (up to 50 % of future offerings for one year) but do not impose voting covenants. No criminal or civil proceedings are reported against the filer.
For investors, the filing signals material insider confidence and establishes Mr. Hafner as the company’s largest known shareholder, potentially aligning board decisions with shareholder value creation. No immediate dilution or earnings impact is indicated, but future conversions of preferred shares and warrant exercises could expand the float.